Fuse H - Search Results

1

Tissue factor expression and prognosis in patients with metastatic prostate cancer.

Akashi T, Furuya Y, Ohta S, Fuse H. Akashi T, et al. Among authors: fuse h. Urology. 2003 Dec;62(6):1078-82. doi: 10.1016/s0090-4295(03)00768-4. Urology. 2003. PMID: 14665359

2

Parathyroid hormone related protein producing penile cancer.

Akashi T, Fuse H, Muraishi Y, Mizuno I, Nagakawa O, Furuya Y. Akashi T, et al. Among authors: fuse h. J Urol. 2002 Jan;167(1):249. J Urol. 2002. PMID: 11743321 No abstract available.

3

Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer.

Furuya Y, Nozaki T, Nagakawa O, Fuse H. Furuya Y, et al. Among authors: fuse h. Endocr J. 2002 Feb;49(1):85-90. doi: 10.1507/endocrj.49.85. Endocr J. 2002. PMID: 12008754 Free article.

4

Serum pro-gastrin-releasing peptide (31-98) in benign prostatic hyperplasia and prostatic carcinoma.

Nagakawa O, Furuya Y, Fujiuchi Y, Fuse H. Nagakawa O, et al. Among authors: fuse h. Urology. 2002 Sep;60(3):527-30. doi: 10.1016/s0090-4295(02)01774-0. Urology. 2002. PMID: 12350511

5

Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer.

Ohta S, Wada H, Nakazaki T, Maeda Y, Nobori T, Shiku H, Nakamura S, Nagakawa O, Furuya Y, Fuse H. Ohta S, et al. Among authors: fuse h. Anticancer Res. 2002 Sep-Oct;22(5):2991-6. Anticancer Res. 2002. PMID: 12530031

6

Prognostic significance of changes in short-term prostate volume and serum prostate-specific antigen after androgen withdrawal in men with metastatic prostate cancer.

Furuya Y, Nagakawa O, Fuse H. Furuya Y, et al. Among authors: fuse h. Urol Int. 2003;70(3):195-9. doi: 10.1159/000068769. Urol Int. 2003. PMID: 12660456

7

Cell proliferation, apoptosis and prognosis in patients with metastatic prostate cancer.

Furuya Y, Kawauchi Y, Fuse H. Furuya Y, et al. Among authors: fuse h. Anticancer Res. 2003 Jan-Feb;23(1B):577-81. Anticancer Res. 2003. PMID: 12680149

8

Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer.

Ohta S, Fuse H, Fujiuchi Y, Nagakawa O, Furuya Y. Ohta S, et al. Among authors: fuse h. Anticancer Res. 2003 May-Jun;23(3C):2945-50. Anticancer Res. 2003. PMID: 12926141

9

Prognostic significance of serum soluble Fas level and its change during regression and progression of advanced prostate cancer.

Furuya Y, Nagakawa O, Fuse H. Furuya Y, et al. Among authors: fuse h. Endocr J. 2003 Oct;50(5):629-33. doi: 10.1507/endocrj.50.629. Endocr J. 2003. PMID: 14614220 Free article.

10

Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer.

Nagakawa O, Yamagishi T, Fujiuchi Y, Junicho A, Akashi T, Nagaike K, Fuse H. Nagakawa O, et al. Among authors: fuse h. Eur Urol. 2005 Oct;48(4):686-90. doi: 10.1016/j.eururo.2005.05.020. Eur Urol. 2005. PMID: 16005141

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

415 results

Search Page

Filters